BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25014775)

  • 1. Effect of CAL-101, a PI3Kδ inhibitor, on ribosomal rna synthesis and cell proliferation in acute myeloid leukemia cells.
    Nguyen LX; Sesay A; Mitchell BS
    Blood Cancer J; 2014 Jul; 4(7):e228. PubMed ID: 25014775
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.
    He Y; Sun L; Xu Y; Fu L; Li Y; Bao X; Fu H; Xie C; Lou L
    Cancer Lett; 2018 Apr; 420():49-59. PubMed ID: 29409989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-δ Inhibitor CAL-101.
    Riyahi N; Safaroghli-Azar A; Sheikh-Zeineddini N; Sayyadi M; Bashash D
    Cancer Invest; 2019; 37(7):311-324. PubMed ID: 31412710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of PI3Kδ inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs].
    Zhang Q; Xia B; Qu F; Yuan T; Guo S; Zhao W; Li Q; Yang H; Wang Y; Zhang Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Oct; 35(10):926-30. PubMed ID: 25339332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
    Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
    J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia.
    Wang X; Zhang X; Li BS; Zhai X; Yang Z; Ding LX; Wang H; Liang C; Zhu W; Ding J; Meng LH
    Oncotarget; 2014 Nov; 5(21):10732-44. PubMed ID: 25313141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
    Lim EL; Cugliandolo FM; Rosner DR; Gyori D; Roychoudhuri R; Okkenhaug K
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.
    Fruman DA; Rommel C
    Cancer Discov; 2011 Dec; 1(7):562-72. PubMed ID: 22586681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
    Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
    Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
    Herman SE; Gordon AL; Wagner AJ; Heerema NA; Zhao W; Flynn JM; Jones J; Andritsos L; Puri KD; Lannutti BJ; Giese NA; Zhang X; Wei L; Byrd JC; Johnson AJ
    Blood; 2010 Sep; 116(12):2078-88. PubMed ID: 20522708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
    Lannutti BJ; Meadows SA; Herman SE; Kashishian A; Steiner B; Johnson AJ; Byrd JC; Tyner JW; Loriaux MM; Deininger M; Druker BJ; Puri KD; Ulrich RG; Giese NA
    Blood; 2011 Jan; 117(2):591-4. PubMed ID: 20959606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
    Okkenhaug K; Graupera M; Vanhaesebroeck B
    Cancer Discov; 2016 Oct; 6(10):1090-1105. PubMed ID: 27655435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.
    Meadows SA; Vega F; Kashishian A; Johnson D; Diehl V; Miller LL; Younes A; Lannutti BJ
    Blood; 2012 Feb; 119(8):1897-900. PubMed ID: 22210877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
    Ikeda H; Hideshima T; Fulciniti M; Perrone G; Miura N; Yasui H; Okawa Y; Kiziltepe T; Santo L; Vallet S; Cristea D; Calabrese E; Gorgun G; Raje NS; Richardson P; Munshi NC; Lannutti BJ; Puri KD; Giese NA; Anderson KC
    Blood; 2010 Sep; 116(9):1460-8. PubMed ID: 20505158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.
    Bodo J; Zhao X; Sharma A; Hill BT; Portell CA; Lannutti BJ; Almasan A; Hsi ED
    Br J Haematol; 2013 Oct; 163(1):72-80. PubMed ID: 23889282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
    Compagno M; Wang Q; Pighi C; Cheong TC; Meng FL; Poggio T; Yeap LS; Karaca E; Blasco RB; Langellotto F; Ambrogio C; Voena C; Wiestner A; Kasar SN; Brown JR; Sun J; Wu CJ; Gostissa M; Alt FW; Chiarle R
    Nature; 2017 Feb; 542(7642):489-493. PubMed ID: 28199309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
    Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
    Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.